- Home
- TECX vs SITC Comparison
TECX vs SITC Comparison
Compare TECX & SITC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- SITC
- Stock Information
- Founded
- TECX 2019
- SITC 1965
- Country
- TECX United States
- SITC United States
- Employees
- TECX N/A
- SITC N/A
- Industry
- TECX
- SITC Real Estate Investment Trusts
- Sector
- TECX
- SITC Real Estate
- Exchange
- TECX Nasdaq
- SITC Nasdaq
- Market Cap
- TECX 387.1M
- SITC 461.0M
- IPO Year
- TECX 2018
- SITC 1993
- Fundamental
- Price
- TECX $19.02
- SITC $8.71
- Analyst Decision
- TECX Buy
- SITC Hold
- Analyst Count
- TECX 6
- SITC 4
- Target Price
- TECX $79.17
- SITC $14.88
- AVG Volume (30 Days)
- TECX 515.4K
- SITC 997.7K
- Earning Date
- TECX 11-06-2025
- SITC 11-05-2025
- Dividend Yield
- TECX N/A
- SITC 55.04%
- EPS Growth
- TECX N/A
- SITC N/A
- EPS
- TECX N/A
- SITC 6.74
- Revenue
- TECX N/A
- SITC $173,351,000.00
- Revenue This Year
- TECX N/A
- SITC N/A
- Revenue Next Year
- TECX N/A
- SITC N/A
- P/E Ratio
- TECX N/A
- SITC $1.24
- Revenue Growth
- TECX N/A
- SITC N/A
- 52 Week Low
- TECX $13.70
- SITC $8.42
- 52 Week High
- TECX $61.07
- SITC $17.30
- Technical
- Relative Strength Index (RSI)
- TECX 61.68
- SITC 41.08
- Support Level
- TECX $16.98
- SITC $8.56
- Resistance Level
- TECX $18.77
- SITC $8.81
- Average True Range (ATR)
- TECX 1.30
- SITC 0.19
- MACD
- TECX 0.54
- SITC 0.07
- Stochastic Oscillator
- TECX 96.12
- SITC 41.67
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing and managing shopping centers.